If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Medical Affairs » Health Outcomes
Download FREE Excerpt
19 Info Graphics
15 Data Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
Payers drive so much revenue for pharmaceutical companies that the industry recognizes the importance of creating and maintaining effective relationships with the payer community. A key aspect of those relationships revolves around providing health outcomes information. The medical affairs function has long been involved in the dissemination of medical information to external stakeholders so, not surprisingly, many pharma companies have turned to this function to aid in payer interactions.
However, medical affairs organizations often face challenges in executing effective payer interactions and maintaining appropriately sized and trained field groups for payer engagement and market access activities.
Best Practices, LLC undertook this benchmarking study to understand the role of medical affairs in critical payer interactions and to highlight strategies for building and maintaining effective relationships with payers. In particular, this study provides benchmarks around payer segmentation and prioritization as well as the optimal field force levels, talent and training for ensuring effective payer relationships.
This study includes segments for large and small companies and US only and global.
This study reflects the data of 29 survey responses from Medical Affairs leaders at 27 biopharmaceutical companies.
Pharmaceutical; Biopharmaceutical; Biotech; Manufacturing; Chemical; Health Care
Abbvie; Alkermes; AstraZeneca; Baxalta; Biogen; CSL Behring; Daiichi Sankyo; EMD Serono; Genentech; Genomic Health; Lundbeck; Incyte; Janssen; Medivation; Mesoblast; Novartis; Pacira Pharmaceuticals; Pfizer; Pharmacyclics; ProStrakan; Santen; Servier; Shire; Teva Pharmaceutical Industries Ltd; Upsher-Smith; ViiV Healthcare